HomeNewslettersHuman Immunology NewsSintilimab in Combination with Stereotactic Body Radiotherapy and Granulocyte-Macrophage Colony-Stimulating Factor in...
Sintilimab in Combination with Stereotactic Body Radiotherapy and Granulocyte-Macrophage Colony-Stimulating Factor in Metastatic Non-small Cell Lung Cancer: The Multicenter SWORD Phase II Trial
This single-arm, multicenter, Phase II trial investigated the triple combination of sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony-stimulating factor in metastatic non-small cell lung cancer.